Yeongduk An, Young-Je Kim, Chung-Sei Kim, Hyeona Yim, Myungseob Kim, Eui-Kyung Lee, Hyeon-Ji Oh, Jun-Hyeok Han, Eunseon Yoo, Sunghyun Kim, Joongseok Woo, Edward R B Moore, Ji-Youn Jung, Wooram Park
Botulinum neurotoxin type A (BoNT/A) induces muscle atrophy by cleaving synaptosomal-associated protein 25. Thus, BoNT/A has been actively utilized for the treatment of masseter and gastrocnemius hypertrophy. In this study, INI101 toxin was newly identified from the CCUG 7968 strain, and its therapeutic efficacy was evaluated both in vitro and in vivo. The INI101 toxin showed identical genetic sequence, amino acid sequence, and protein subunit composition to BoNT/A produced from strain Hall A. Electromyography (EMG), and immunofluorescence staining demonstrated that INI101 (at 2 ~ 8 U/rat) effectively blocked the neuromuscular junction with no toxicity in a rat model...
December 2021: Applied Microbiology and Biotechnology